Immunological Reviews最新文献_第6页

From the Gorgon's blood to Behring's Blutserumtherapie: A long path towards serum therapy 从高竿之血到贝林的血清疗法：通往血清疗法的漫长之路

IF 7.5 2区医学

Immunological Reviews Pub Date : 2024-09-14 DOI: 10.1111/imr.13391

Yves-Marie Lahaie, Hervé Watier

{"title":"From the Gorgon's blood to Behring's Blutserumtherapie: A long path towards serum therapy","authors":"Yves-Marie Lahaie, Hervé Watier","doi":"10.1111/imr.13391","DOIUrl":"10.1111/imr.13391","url":null,"abstract":"<div>\u0000 \u0000 At the end of the 19th century medicine was turned upside down by the development of serum therapy, a great therapeutic revolution as was vaccination a few years earlier. Many serums were developed, the most famous being the German doctor Emil von Behring's diphtheria serum, which saved countless children's lives from this dreadful disease. The discovery of the serum therapy principle, allowed by the progressive understanding of humoral immunity, occurred both in Germany and France, almost at the same time. Interestingly, this principle arose from two different intellectual paths, reviving the age-old opposition between mechanism and vitalism: while Behring came to this discovery reasoning as a chemist, French researchers Charles Richet and Jules Héricourt behaved as physiologists, focusing on the role of the host in the host-pathogen interaction. However, we should maybe consider that serum therapy history begins much earlier. Great forerunners must not be forgotten, especially researchers who investigated the field of immunity as soon as in the very beginning of the microbiological revolution; but also many people throughout centuries who tried to cure diseases with blood: as a transfer of blood serum, serum therapy also lies in the tradition of blood transfusion.\u0000 </div>","PeriodicalId":178,"journal":{"name":"Immunological Reviews","volume":"328 1","pages":"13-23"},"PeriodicalIF":7.5,"publicationDate":"2024-09-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142259461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Fc-FcγR interactions during infections: From neutralizing antibodies to antibody-dependent enhancement 感染期间 Fc-FcγR 的相互作用：从中和抗体到抗体依赖性增强

IF 7.5 2区医学

Immunological Reviews Pub Date : 2024-09-13 DOI: 10.1111/imr.13393

Julia E. Edgar, Stylianos Bournazos

{"title":"Fc-FcγR interactions during infections: From neutralizing antibodies to antibody-dependent enhancement","authors":"Julia E. Edgar, Stylianos Bournazos","doi":"10.1111/imr.13393","DOIUrl":"10.1111/imr.13393","url":null,"abstract":"Advances in antibody technologies have resulted in the development of potent antibody-based therapeutics with proven clinical efficacy against infectious diseases. Several monoclonal antibodies (mAbs), mainly against viruses such as SARS-CoV-2, HIV-1, Ebola virus, influenza virus, and hepatitis B virus, are currently undergoing clinical testing or are already in use. Although these mAbs exhibit potent neutralizing activity that effectively blocks host cell infection, their antiviral activity results not only from Fab-mediated virus neutralization, but also from the protective effector functions mediated through the interaction of their Fc domains with Fcγ receptors (FcγRs) on effector leukocytes. Fc-FcγR interactions confer pleiotropic protective activities, including the clearance of opsonized virions and infected cells, as well as the induction of antiviral T-cell responses. However, excessive or inappropriate activation of specific FcγR pathways can lead to disease enhancement and exacerbated pathology, as seen in the context of dengue virus infections. A comprehensive understanding of the diversity of Fc effector functions during infection has guided the development of engineered antiviral antibodies optimized for maximal effector activity, as well as the design of targeted therapeutic approaches to prevent antibody-dependent enhancement of disease.","PeriodicalId":178,"journal":{"name":"Immunological Reviews","volume":"328 1","pages":"221-242"},"PeriodicalIF":7.5,"publicationDate":"2024-09-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/imr.13393","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142259464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Immune checkpoint inhibitors in infectious disease 传染病中的免疫检查点抑制剂。

IF 7.5 2区医学

Immunological Reviews Pub Date : 2024-09-09 DOI: 10.1111/imr.13388

Hannah A. D. King, Sharon R. Lewin

{"title":"Immune checkpoint inhibitors in infectious disease","authors":"Hannah A. D. King, Sharon R. Lewin","doi":"10.1111/imr.13388","DOIUrl":"10.1111/imr.13388","url":null,"abstract":"Following success in cancer immunotherapy, immune checkpoint blockade is emerging as an exciting potential treatment for some infectious diseases, specifically two chronic viral infections, HIV and hepatitis B. Here, we will discuss the function of immune checkpoints, their role in infectious disease pathology, and the ability of immune checkpoint blockade to reinvigorate the immune response. We focus on blockade of programmed cell death 1 (PD-1) to induce durable immune-mediated control of HIV, given that anti-PD-1 can restore function to exhausted HIV-specific T cells and also reverse HIV latency, a long-lived form of viral infection. We highlight several key studies and future directions of research in relation to anti-PD-1 and HIV persistence from our group, including the impact of immune checkpoint blockade on the establishment (AIDS, 2018, 32, 1491), maintenance (PLoS Pathog, 2016, 12, e1005761; J Infect Dis, 2017, 215, 911; Cell Rep Med, 2022, 3, 100766) and reversal of HIV latency (Nat Commun, 2019, 10, 814; J Immunol, 2020, 204, 1242), enhancement of HIV-specific T cell function (J Immunol, 2022, 208, 54; iScience, 2023, 26, 108165), and investigating the effects of anti-PD-1 and anti-CTLA-4 in vivo in people with HIV on ART with cancer (Sci Transl Med, 2022, 14, eabl3836; AIDS, 2021, 35, 1631; Clin Infect Dis, 2021, 73, e1973). Our future work will focus on the impact of anti-PD-1 in vivo in people with HIV on ART without cancer and potential combinations of anti-PD-1 with other interventions, including therapeutic vaccines or antibodies and less toxic immune checkpoint blockers.","PeriodicalId":178,"journal":{"name":"Immunological Reviews","volume":"328 1","pages":"350-371"},"PeriodicalIF":7.5,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/imr.13388","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142152720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pathogenic role of anti-nuclear autoantibodies in systemic sclerosis: Insights from other rheumatic diseases 抗核自身抗体在系统性硬化症中的致病作用：其他风湿病的启示。

IF 7.5 2区医学

Immunological Reviews Pub Date : 2024-09-09 DOI: 10.1111/imr.13390

Wieke M. van Oostveen, Tom W. J. Huizinga, Cynthia M. Fehres

{"title":"Pathogenic role of anti-nuclear autoantibodies in systemic sclerosis: Insights from other rheumatic diseases","authors":"Wieke M. van Oostveen, Tom W. J. Huizinga, Cynthia M. Fehres","doi":"10.1111/imr.13390","DOIUrl":"10.1111/imr.13390","url":null,"abstract":"Systemic sclerosis (SSc) is a severe autoimmune disease characterized by vasculopathy, fibrosis, and dysregulated immunity, with hallmark autoantibodies targeting nuclear antigens such as centromere protein (ACA) and topoisomerase I (ATA). These autoantibodies are highly prevalent and disease-specific, rarely coexisting, thus serving as crucial biomarkers for SSc diagnosis. Despite their diagnostic value, their roles in SSc pathogenesis remain unclear. This review summarizes current literature on ACA and ATA in SSc, comparing them to autoantibodies in other rheumatic diseases to elucidate their potential pathogenic roles. Similarities are drawn with anti-citrullinated protein antibodies (ACPA) in rheumatoid arthritis, particularly regarding disease specificity and minimal pathogenic impact of antigen binding. In addition, differences between ANA and ACPA in therapeutic responses and Fab glycosylation patterns are reviewed. While ACA and ATA are valuable for disease stratification and monitoring activity, understanding their origins and the associated B cell responses is critical for advancing therapeutic strategies for SSc.","PeriodicalId":178,"journal":{"name":"Immunological Reviews","volume":"328 1","pages":"265-282"},"PeriodicalIF":7.5,"publicationDate":"2024-09-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/imr.13390","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142152721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Janus (dual) model of immunoglobulin isotype evolution: Conservation and plasticity are the defining paradigms 免疫球蛋白同种型进化的 Janus（双重）模式：守恒性和可塑性是决定性的范式。

IF 7.5 2区医学

Immunological Reviews Pub Date : 2024-09-03 DOI: 10.1111/imr.13389

Martin F. Flajnik

{"title":"The Janus (dual) model of immunoglobulin isotype evolution: Conservation and plasticity are the defining paradigms","authors":"Martin F. Flajnik","doi":"10.1111/imr.13389","DOIUrl":"10.1111/imr.13389","url":null,"abstract":"<div>\u0000 \u0000 The study of antibodies in jawed vertebrates (gnathostomes) provides every immunologist with a bird's eye view of how human immunoglobulins (Igs) came into existence and subsequently evolved into their present forms. It is a fascinating Darwinian history of conservation on the one hand and flexibility on the other, exemplified by the Ig heavy chain (H) isotypes IgM and IgD/W, respectively. The cartilaginous fish (e.g., sharks) Igs provide a glimpse of “how everything got off the ground,” while the amphibians (e.g., the model Xenopus) reveal how the adaptive immune system made an about face with the emergence of Ig isotype switching and IgG-like structure/function. The evolution of mucosal Igs is a captivating account of malleability, convergence, and conservation, and a call to arms for future study! In between there are spellbinding chronicles of antibody evolution in each class of vertebrates and rather incredible stories of how antibodies can adapt to occupy niches, for example, single-domain variable regions, cold-adapted Igs, convergent mechanisms to dampen antibody function, provision of mucosal defense, and many more. The purpose here is not to provide an encyclopedic examination of antibody evolution, but rather to hit the high points and entice readers to appreciate how things “came to be.”\u0000 </div>","PeriodicalId":178,"journal":{"name":"Immunological Reviews","volume":"328 1","pages":"49-64"},"PeriodicalIF":7.5,"publicationDate":"2024-09-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142118556","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Nanobody-based heavy chain antibodies and chimeric antibodies 基于纳米抗体的重链抗体和嵌合抗体。

IF 7.5 2区医学

Immunological Reviews Pub Date : 2024-08-30 DOI: 10.1111/imr.13385

Friedrich Koch-Nolte

引用次数: 0

The function of antibodies 抗体的功能。

IF 7.5 2区医学

Immunological Reviews Pub Date : 2024-08-24 DOI: 10.1111/imr.13387

Marc Daëron

{"title":"The function of antibodies","authors":"Marc Daëron","doi":"10.1111/imr.13387","DOIUrl":"10.1111/imr.13387","url":null,"abstract":"<div>\u0000 \u0000 Antibodies have multiple biological activities. They can both recognize and act on specific antigens. They can protect against and cause serious diseases, enhance and inhibit antibody responses, enable survival, and threaten life. Which among their many, often antagonistic properties explains that antibodies were selected half a billion years ago and transmitted to mammals across millions of generations? In other words, what is the function of antibodies? Here I examine how their structure endows antibodies with unique cognitive and effector properties that contribute to their multiple biological activities. I show that rather than specific properties, antibodies have large functional repertoires. They have a cognitive repertoire and an effector repertoire that are selected from larger available repertoires, themselves drawn at random from even larger virtual repertoires. These virtual repertoires provide the adaptive immune system with immense, constantly renewed, reservoirs of cognitive and effector functions that can be actualized at any time according to the context. I propose that such a flexibility, which enables living individuals to adapt to a rapidly changing environment, and even deal with an unknown future, may provide a better selective advantage than any particular function.\u0000 </div>","PeriodicalId":178,"journal":{"name":"Immunological Reviews","volume":"328 1","pages":"113-125"},"PeriodicalIF":7.5,"publicationDate":"2024-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142046033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Natural killer cells and engagers: Powerful weapons against cancer 自然杀伤细胞和吞噬细胞：对抗癌症的强大武器

IF 7.5 2区医学

Immunological Reviews Pub Date : 2024-08-24 DOI: 10.1111/imr.13384

Cristina Bottino, Valentin Picant, Eric Vivier, Roberta Castriconi

{"title":"Natural killer cells and engagers: Powerful weapons against cancer","authors":"Cristina Bottino, Valentin Picant, Eric Vivier, Roberta Castriconi","doi":"10.1111/imr.13384","DOIUrl":"10.1111/imr.13384","url":null,"abstract":"Natural killer (NK) cells are innate immune effectors whose functions rely on receptors binding cytokines, recognizing self-molecules, or detecting danger signals expressed by virus-infected or tumor cells. The potent cytotoxic potential makes NK cells promising candidates for cancer immunotherapy. To enhance their activity strategies include cytokine administration, blocking of immune checkpoints, and designing of antibody-based NK cell engagers (NKCEs). NKCEs represent a cutting-edge approach to cancer therapy: they strengthen the NK-to-target cell interactions and optimize tumor killing, possibly overcoming the immunosuppressive tumor microenvironment. NK cells belong to the innate lymphoid cells (ILCs) and are categorized into different subsets also including cells with a memory-like phenotype: this complexity needs to be explored in the context of cancer immunotherapy, particularly when designing NKCEs. Two strategies to enhance NK cell activity in cancer patients can be adopted: activating patients' own NK cells versus the adoptive transfer of ex vivo activated NK cells. Furthermore, the capability of NKCEs to activate γδ T cells could have a significant synergistic effect in immunotherapy.","PeriodicalId":178,"journal":{"name":"Immunological Reviews","volume":"328 1","pages":"412-421"},"PeriodicalIF":7.5,"publicationDate":"2024-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/imr.13384","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142046032","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antibody feedback regulation 抗体反馈调节。

IF 7.5 2区医学

Immunological Reviews Pub Date : 2024-08-23 DOI: 10.1111/imr.13377

Birgitta Heyman

{"title":"Antibody feedback regulation","authors":"Birgitta Heyman","doi":"10.1111/imr.13377","DOIUrl":"10.1111/imr.13377","url":null,"abstract":"Antibodies are able to up- or downregulate antibody responses to the antigen they bind. Two major mechanisms can be distinguished. Suppression is most likely caused by epitope masking and can be induced by all isotypes tested (IgG1, IgG2a, IgG2b, IgG3, IgM, and IgE). Enhancement is often caused by the redistribution of antigen in a favorable way, either for presentation to B cells via follicular dendritic cells (IgM and IgG3) or to CD4+ T cells via dendritic cells (IgE, IgG1, IgG2a, and IgG2b). IgM and IgG3 complexes activate complement and are transported from the marginal zone to follicles by marginal zone B cells expressing complement receptors. IgE–antigen complexes are captured by CD23+ B cells in the blood and transported to follicles, delivered to CD8α+ conventional dendritic cells, and presented to CD4+ T cells. Enhancement of antibody responses by IgG1, IgG2a, and IgG2b in complex with proteins requires activating FcγRs. These immune complexes are captured by dendritic cells and presented to CD4+ T cells, subsequently helping cognate B cells. Endogenous feedback regulation influences the response to booster doses of vaccines and passive administration of anti-RhD antibodies is used to prevent alloimmunization of RhD-negative women carrying RhD-positive fetuses.","PeriodicalId":178,"journal":{"name":"Immunological Reviews","volume":"328 1","pages":"126-142"},"PeriodicalIF":7.5,"publicationDate":"2024-08-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/imr.13377","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142046031","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Single domain antibody: Development and application in biotechnology and biopharma 单域抗体：生物技术和生物制药领域的开发与应用。

IF 7.5 2区医学

Immunological Reviews Pub Date : 2024-08-21 DOI: 10.1111/imr.13381

Ting Yu, Fang Zheng, Wenbo He, Serge Muyldermans, Yurong Wen

{"title":"Single domain antibody: Development and application in biotechnology and biopharma","authors":"Ting Yu, Fang Zheng, Wenbo He, Serge Muyldermans, Yurong Wen","doi":"10.1111/imr.13381","DOIUrl":"10.1111/imr.13381","url":null,"abstract":"Heavy-chain antibodies (HCAbs) are a unique type of antibodies devoid of light chains, and comprised of two heavy chains-only that recognize their cognate antigen by virtue of a single variable domain also referred to as VHH, single domain antibody (sdAb), or nanobody (Nb). These functional HCAbs, serendipitous discovered about three decades ago, are exclusively found in camelids, comprising dromedaries, camels, llamas, and vicugnas. Nanobodies have become an essential tool in biomedical research and medicine, both in diagnostics and therapeutics due to their beneficial properties: small size, high stability, strong antigen-binding affinity, low immunogenicity, low production cost, and straightforward engineering into more potent affinity reagents. The occurrence of HCAbs in camelids remains intriguing. It is believed to be an evolutionary adaptation, equipping camelids with a robust adaptive immune defense suitable to respond to the pressure from a pathogenic invasion necessitating a more profound antigen recognition and neutralization. This evolutionary innovation led to a simplified HCAb structure, possibly supported by genetic mutations and drift, allowing adaptive mutation and diversification in the heavy chain variable gene and constant gene regions. Beyond understanding their origins, the application of nanobodies has significantly advanced over the past 30 years. Alongside expanding laboratory research, there has been a rapid increase in patent application for nanobodies. The introduction of commercial nanobody drugs such as Cablivi, Nanozora, Envafolimab, and Carvykti has boosted confidence among in their potential. This review explores the evolutionary history of HCAbs, their ontogeny, and applications in biotechnology and pharmaceuticals, focusing on approved and ongoing medical research pipelines.","PeriodicalId":178,"journal":{"name":"Immunological Reviews","volume":"328 1","pages":"98-112"},"PeriodicalIF":7.5,"publicationDate":"2024-08-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/imr.13381","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142015737","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0